BYN-002 Antibody Shows Potential for Long-Interval Dosing
The Phase 1 interim data suggests that Fc-engineered antibodies could enable maintenance dosing every three to six months.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that new long-acting medications will effectively simplify treatment routines for chronic illnesses?
Bionyra Pharma has released interim Phase 1 clinical trial data for BYN-002, an investigational anti-TL1A antibody. The study indicates a terminal half-life of up to 82 days in multiple-dose cohorts, suggesting a potential for infrequent maintenance dosing in inflammatory bowel disease.
Why it matters
Extending the dosing interval for anti-TL1A treatments could significantly reduce the administration burden for patients with inflammatory bowel disease. Bionyra aims to achieve maintenance regimens of every three to six months using this engineered antibody.
The study recorded a terminal half-life of 78 to 82 days in multiple-dose cohorts. Researchers achieved this using YTE substitutions to extend half-life and LALA substitutions to reduce Fc-mediated effector functions.
The players
Bionyra Pharma
A developer of antibody-based therapeutics focused on reducing administration frequency for chronic inflammatory conditions.
The details
BYN-002 is an antibody engineered with specific modifications in its Fc region—the constant fragment that determines how the antibody interacts with the immune system. The YTE (Tyrosine, Threonine, Glutamate) substitution is a protein engineering technique designed to increase binding to the neonatal Fc receptor, thereby extending the molecule's time in the bloodstream. The LALA (Leucine to Alanine) substitution prevents the antibody from triggering unwanted immune activation by reducing Fc-mediated effector functions, such as cell killing or cytokine release.
Timeline
June 2026: Bionyra Pharma launched.
April 2026: Phase 1 study of BYN-003 began.
October 2026: Interim results were presented at UEG Week 2026.
The Tech Race
Bionyra is positioning BYN-002 within the competitive field of anti-TL1A antibody research. The firm is specifically aiming to differentiate its candidate by targeting an extended dosing schedule of every three to six months.
This development currently impacts researchers and clinicians monitoring progress toward more convenient, long-interval dosing for inflammatory bowel disease patients. Future availability depends on successful completion of subsequent, larger-scale clinical trials.
The takeaway
The engineering of YTE and LALA substitutions in BYN-002 effectively extends its terminal half-life to over two months. Interested stakeholders should watch for upcoming Phase 2 trial enrollment announcements to confirm whether these pharmacokinetic results translate into sustained therapeutic efficacy.
Further reading
For broader trends in pharmacological engineering, see our Biotech section.
Live Poll
Do you trust that new long-acting medications will effectively simplify treatment routines for chronic illnesses?
